Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Prone Positioning and Thoracoabdominal Binding on Lung and Muscle Protection in ARDS Patients During Spontaneous Breathing

23 settembre 2026 aggiornato da: Rodrigo Cornejo, University of Chile

Effect of Prone Positioning and Thoracoabdominal Binding on Lung and Muscle Protection in ARDS Patients With ICU-acquired Weakness Transitioning From Controlled to Spontaneous Breathing

Ventilator-induced diaphragmatic dysfunction and intensive care unit (ICU)-acquired weakness are two consequences of prolonged mechanical ventilation and critical illness in patients with acute respiratory distress syndrome (ARDS). Both complicate the process of withdrawing mechanical ventilation, increase hospital mortality and cause chronic disability in survivors. During transition from controlled to spontaneous breathing, these complications of critical illness favor an abnormal respiratory pattern and recruit accessory respiratory muscles which may promote additional lung and muscle injury. The type of ventilatory support and positioning may affect the muscle dysfunction and patient-self-inflicted lung injury at spontaneous breathing onset. In that regard, ARDS patients with ventilator-induced diaphragmatic dysfunction and ICU-acquired weakness who are transitioning from controlled to partial ventilatory support probably present an abnormal respiratory pattern which exacerbates lung and muscle injury. Physiological-oriented ventilatory approaches based on prone positioning or semi recumbent positioning with abdominal binding at spontaneous breathing onset, could decrease lung and muscle injury by favoring a better neuromuscular efficiency, and preventing intense inspiratory efforts and high transpulmonary driving pressures, as well as high-magnitude pendelluft. In the current project, in addition to perform a multimodal description of the severity of ventilator-induced diaphragmatic dysfunction and ICU-acquired weakness in prolonged mechanically ventilated ARDS patients, prone positioning and supine plus thoracoabdominal binding at spontaneous breathing onset will be evaluated.

Panoramica dello studio

Stato

Terminato

Condizioni

Intervento / Trattamento

Descrizione dettagliata

The study was designed in three phases: a multimodal physiological description, a randomized crossover trial, and a pilot randomized trial. The multimodal physiological description and the randomized crossover trial were conducted in the same cohort. The pilot randomized trial was not conducted.

Multimodal Physiological Description Phase: a multimodal physiological description was performed to characterize ICU acquired weakness and ventilator-induced diaphragm dysfunction in prolonged mechanically ventilated ARDS patients at spontaneous breathing onset, in pressure support ventilation mode. The assessments included conventional electromyography (cEMG); electrical activity of the diaphragm; respiratory muscle ultrasound; respiratory flow; tidal volume; airway, esophageal and gastric pressures; and hemodynamic and electrical impedance tomography monitoring. Diaphragm ultrasound and cEMG were performed after the crossover trial, to avoid reducing PEEP and PS to the standardized low values required for diaphragm ultrasound (PEEP and PS of 6 cmH2O) before the crossover conditions, which could alter respiratory mechanics at protocol entry; cEMG findings were not expected to change over this timeframe (amendment approved by IRB No. 45/2024; May 15, 2024).

Randomized Crossover Trial Phase: Patients were asigened in random order to three 60-minute conditions on pressure support ventilation mode: A.- Control group: semi-recumbent position at 45º (previously described as supine at 45º), B.- Thoracoabdominal binding: semi-recumbent position at 45º plus thoracoabdominal binding, C.- Prone positioning (without thoracoabdominal binding). These strategies were performed under individualized PEEP (obtained at the lowest combination of collapse and overdistension according to electrical impedance tomography), with 15-minute washout periods of in assisted/controlled ventilation between conditions.

Pilot Randomized Trial Phase: This phase was designed to randomize patients to one of the three strategies under standard PEEP (ARDSNet strategy), with PET/CT imaging and biomarker analysis. The originally registered enrollment (n = 36) corresponded to this phase. A protocol amendment approved by the local ethics committee in May 2024 established that patients enrolled in this phase were not required to have completed the multimodal description and crossover phases, and reduced the planned sample size to 12 patients due to budgetary and logistical constraints. The phase was ultimately not conducted; the decision not to conduct it was reported to the local ethics committee and approved by the national funding agency.

Enrollment: The target enrollment for the crossover phase (24 patients) was established in the May 2024 protocol amendment. Recruitment was closed after 14 patients had been enrolled.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

14

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

      • Independencia, Chile
        • Hospital Clínico Universidad de Chile

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Adult ARDS patients with moderate-severe ARDS on controlled protective mechanical ventilation for more than 2 days (modified from "more than 3 days" by the protocol amendment approved in May 2024)
  • Stable hemodynamics
  • Level of consciousness enough to initiate spontaneous breathing

Exclusion Criteria:

  • Unstable hemodynamics
  • Tracheostomy
  • Abnormal level of consciousness
  • Central nervous system injury
  • Esophageal varices
  • Pregnancy
  • Contraindications for installation of electrical impedance tomography or nasogastric catheter placement
  • Contraindications for prone positioning and thoracoabdominal binding
  • Chronic neuromuscular disorders
  • Obstructive lung disease; intrinsic positive end-expiratory pressure (PEEP) ≥3 cmH₂O (measured without inspiratory effort);
  • Recent-onset sepsis and moderate-to-severe metabolic acidosis;
  • Multi-organ failure with high short-term mortality risk
  • Clinical evidence of respiratory or hemodynamic instability

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Terapia di supporto
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione incrociata
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore attivo: Control Group

ARDS patients at spontaneous breathing onset on pressure support ventilation mode in semi-recumbent position at 45º degrees, performed under individualized PEEP applied in random order.

ARDS patients at spontaneous breathing onset on pressure support ventilation mode in supine position at 45º degrees, performed under standard PEEP according to ARDSNet strategy and individualized PEEP applied in random order.

Sperimentale: Prone Positioning

ARDS patients at spontaneous breathing onset on pressure support ventilation mode in prone position, performed under individualized PEEP applied in random order.

Prone positioning will be performed according to ICU local protocol with trained provider teams.

Sperimentale: Thoracoabdominal Binding

ARDS patients at spontaneous breathing onset on pressure support ventilation mode in semi-recumbent position at 45º degrees using thoracoabdominal binding with the binder's upper edge above the costal margin, performed under individualized PEEP applied in random order.

Thoracoabdominal binding will be used in semi-recumbent position (at 45º) and titrated to obtain a approximately 20% decrease in chest wall compliance and 1-3 cm H2O increase in end-expiratory gastric pressure during steady-state breathing

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
(Randomized Crossover Trial Phase) Pendelluft Magnitude
Lasso di tempo: One hour on each ventilatory strategy

Pendelluft magnitude monitored by electrical impedance tomography, analyzed as a continuous variable. Title corrected in September 2026 from "High-Magnitude Pendelluft", as no threshold was prespecified and the sample size calculation was based on a continuous outcome, according to the protocol amendment approved in May 2024.

One hour on each ventilatory strategy
(Randomized Crossover Trial Phase) Neuromechanical Coupling of the Diaphragm
Lasso di tempo: One hour on each ventilatory strategy

Ratio between transdiaphragmatic pressure and electrical activity of the diaphragm, measured by an esophageal/gastric catheter. Co-primary outcome with pendelluft magnitude. Prespecified as primary in the ethics-approved protocol and described in the Brief Summary and as a secondary outcome of the Pilot Randomized Trial Phase, but omitted in error from the Crossover Phase outcomes in the original registration. Added in September 2026.

One hour on each ventilatory strategy

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
(Randomized Crossover Trial Phase) Respiratory Mechanics Variables
Lasso di tempo: One hour on each ventilatory strategy

Esophageal pressure swing, gastric pressure, transdiaphragmatic pressure and transpulmonary driving pressure measured by a esophageal/gastric catheter

One hour on each ventilatory strategy

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Collaboratori

Investigatori

  • Investigatore principale: Rodrigo Cornejo, University of Chile

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

6 dicembre 2023

Completamento primario (Effettivo)

28 agosto 2025

Completamento dello studio (Effettivo)

28 agosto 2025

Date di iscrizione allo studio

Primo inviato

6 marzo 2023

Primo inviato che soddisfa i criteri di controllo qualità

21 aprile 2023

Primo Inserito (Effettivo)

24 aprile 2023

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

28 settembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

23 settembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • 1221829

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

De-identified individual participant data underlying the published results will be available upon reasonable request to the principal investigator, subject to approval by the local ethics committee and a data use agreement.

Periodo di condivisione IPD

Beginning after publication, for 5 years.

Criteri di accesso alla condivisione IPD

Researchers with a methodologically sound proposal, after ethics committee approval.

Tipo di informazioni di supporto alla condivisione IPD

  • STUDIO_PROTOCOLLO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .